The Open AIDS Journal

ISSN: 1874-6136 ― Volume 15, 2021

Implications of Patent Pools on Innovation Regarding Antiretrovirals§

Eric Noehrenberg*
Noehrenberg International Policy Consultancy, Geneva, Switzerland


Patent pools have been promoted as an innovative means of promoting the production of fixed-dose combination antiretroviral medicines (ARVs), which can be particularly appropriate for resource-poor settings. An important question, however, is what are the implications of patent pools on innovation for creating new and improved antiretrovirals. Indeed, given the continuing mutation of HIV and growing resistance to existing treatments, continued innovation in ARV development is vital for addressing these challenges. Would patent pools be a hindrance or rather a stimulus for further innovation? This question is particularly relevant in light of UNITAID’s initiative to create a patent pool for ARV development, focusing on pediatric formulations and new combinations, by the end of 2009.

In this article, the author argues that a voluntary and well-designed patent pool, involving both innovative and generic manufacturers, focused on developing fixed-dose combinations for resource-poor markets with the greatest need, could actually stimulate increased innovation to meet these needs. Indeed, by bringing together the major ARV producers worldwide to collaborate on developing products which will meet the needs of the poorest, an ARV patent pool could create significant public health benefits. UNITAID has taken the lead in designing and implementing such a pool and UNITAID’s experience will have important lessons for policy-makers in the future.

Article Information

Identifiers and Pagination:

Year: 2010
Volume: 4
First Page: 67
Last Page: 69
Publisher Id: TOAIDJ-4-67
DOI: 10.2174/1874613601004020067

Article History:

Received Date: 16/6/2009
Revision Received Date: 1/7/2009
Acceptance Date: 1/8/2009
Collection year: 1/2010
Electronic publication date: 19/1/2010

© Eric Noehrenberg; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Noehrenberg International Policy Consultancy, Geneva, Switzerland; E-mail:§ Please note that the opinions expressed in this article are purely Dr. Noehrenberg’s own personal opinions and should not be seen as reflecting the positions of Dr. Noehrenberg’s present or past employers.

Track Your Manuscript:


"Publishing with Bentham Open was a great experience. The timeliness and communication were outstanding. I am hopeful that I will have the opportunity to publish with Bentham Open again in the future."

Dr. Daniel B. Chastain
Pharm.D., AAHIVP, Clinical Pharmacy Specialist, Infectious Diseases, Phoebe Health, USA

SCImago Journal Ranking

SCImago Journal & Country Rank

Browse Contents

Webmaster Contact:
Copyright © 2021 Bentham Open